Effect of topical oxytocin gel on vaginal mucosa in postmenopausal Egyptian women: a clinical randomized trial

What Was Tested

This randomized controlled trial paper looks at Oxytocin.

The study aimed to investigate the effect of intravaginally applied oxytocin on expressions of vaginal atrophy.

Why It Was Studied

Vaginal atrophy is common after menopause and is often linked to sexual dysfunction, particularly dyspareunia.

Strengths include studying different outcomes of applying the oxytocin gel for vaginal atrophy.

Who Took Part

PubMed tags the participants as women only.

Fifty postmenopausal women aged 47 to 66 years with vaginal atrophy participated in this double-blinded placebo-controlled study.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Oxytocin study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Oxytocin group a baseline to be compared against.

The gel consisted of hypromellose, pH 3.8 (Vagovital).

What Was Measured

Strengths include studying different outcomes of applying the oxytocin gel for vaginal atrophy.

The subject headings attached to it are Oxytocin, Postmenopause, Egypt, Vagina, Administration, Intravaginal, Vaginal Diseases and Atrophy.

Author keywords: vaginal mucosa, vaginal pH and vaginal smear.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (The journal of sexual medicine), a journal based in Netherlands.

More context: the Oxytocin compound page, all human trials.